Second quarter 2023 results

Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

14:30 -16:00 CET | 8:30am – 10am EST

Featuring

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Specialty Care

Olivier Charmeil

General Medicines

Dietmar Berger

Global Head of R&D ad interim

Thomas Triomphe

Vaccines

Julie van Ongevalle

Consumer Healthcare

Roy Papatheodorou

General Counsel

Highlights

We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.